Update on application for conditional marketing authorisation for the AstraZeneca COVID-19 vaccine to the European Medicines Agency

AstraZeneca has submitted a substantial data package to support a possible application for conditional marketing authorisation for its COVID-19 vaccine to the European Medicines Agency. The Company has been submitting data on a rolling basis and will continue to work closely with the EMA to support the start of a formal CMA application process. A similar approach of data provision on a rolling basis been taken with other regulators around the world.